Solid Biosciences

Barclays Global Healthcare Conference

March 14, 2023

SOLID BIOSCIENCES

Forward Looking Statement

This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the company; the anticipated milestones, business focus and pipeline of the company; the cash runway of the company and the sufficiency of the company’s cash and investments to fund its operations; the company’s SGT-003 program, including expectations for filing an IND and initiating dosing, AVB-202 program, including expectations for filing an IND, and AVB-401 program; the company’s plans to present data from IGNITE DMD; the implication of preclinical data; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the ability to recognize the anticipated benefits of Solid’s acquisition of AavantiBio; the outcome of any legal proceedings that may be instituted against Solid or AavantiBio following the announcement of the acquisition and related transactions; the ability to obtain or maintain the listing of the common stock of the combined company on the Nasdaq Stock Market following the acquisition; the company’s ability to advance its SGT-003, AVB-202, AVB-401 and other programs on the timelines expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; obtain and maintain the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring board; replicate in clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; whether the methodologies, assumptions and applications the company utilizes to assess particular safety or efficacy parameters will yield meaningful statistical results; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; successfully transition, optimize and scale its manufacturing process; obtain, maintain or protect intellectual property rights related to its product candidates; compete successfully with other companies that are seeking to develop Duchenne and Friedreich’s ataxia treatments and gene therapies; manage expenses; and raise the substantial additional capital needed, on the timeline necessary, to continue development of SGT-003, AVB-202, AVB-401 and other product candidates, achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.

2023 Expected To Be a Year of Transformation and Meaningful Advancements for Solid

Strategic pipeline of programs continuing to evolve with anticipated key milestones in 2023-2024

PEOPLE
Led by experienced team with deep expertise in precision genetic medicine



PROCESS
Differentiated CMC expertise, building a robust, scalable manufacturing process utilizing transient transfection



PIPELINE
Opportunity to become a leading precision genetic medicines company within neuromuscular and cardiac genetic medicine

Solid has the people, process and pipeline to be a leader in precision genetic medicines for rare neuromuscular and cardiac diseases.

SOLID BIOSCIENCES

Led By Experienced Team With Deep Expertise in Precision Genetic Medicine

Bo Cumbo
President and CEO

AAVANTIBIO · SAREPTA THERAPEUTICS · VERTEX · GILEAD

Ty Howton, J.D.
Chief Administrative Officer

AAVANTIBIO · SAREPTA THERAPEUTICS · VERTEX · Genentech — A Member of the Roche Group

Kevin Tan
Chief Financial Officer

Selecta Biosciences · SAREPTA THERAPEUTICS · CPP Investments · MACQUARIE

Jessie Hanrahan, Ph.D.
Chief Regulatory Officer

AAVANTIBIO · bluebirdbio · SANOFI GENZYME · Boston Scientific

Carl Morris, Ph.D.
Chief Scientific Officer Neuromuscular

Pfizer

Jenny Marlowe, Ph.D.
Chief Scientific Officer Friedreich's Ataxia & Cardiac Pipeline

AAVANTIBIO · NOVARTIS · bluebirdbio

Paul Herzich
Chief Technology Officer

AAVANTIBIO · NOVARTIS · bridgebio · LogicBio THERAPEUTICS

Roxana Donisa Dreghici, M.D.
Head of Clinical Development

Roche · santhera — THEIR FUTURE - OUR FOCUS

Merger Solidifies Solid as a Gene Therapy Platform Technology Company



Solid is Well-Positioned to Execute on Multiple Programs in the Coming Years

Diversified Pipeline with Multiple Programs at Different Stages

Indications With High Unmet Need and Significant Market Opportunities

Program	Indication	Research / Discovery	Preclinical	IND submission (Anticipated)
NEUROMUSCULAR				
SGT-003 (AAV-SLB101)	Duchenne			2H 2023
AVB-202 - TT (cardiac and neuromuscular manifestations)	Friedreich's Ataxia			
CARDIAC				
AVB-401 (Dilated Cardiomyopathy (DCM))	BAG3-Mediated DCM			
AVB-501 (Dilated Cardiomyopathy (DCM))	Undisclosed			
AVB-601 (Hypertrophic Cardiomyopathy)	Undisclosed			

Notes: In 2020, Solid entered into a collaboration agreement with Ultragenyx for the development of UX810, a next generation Duchenne construct comprised of Solid's proprietary nNOS microdystrophin and Ultragenyx's HeLa PCL manufacturing platform for use with AAV8 and Clade E variants thereof. Solid has the option to co-fund collaboration programs in return for a profit share or increased royalty payments at proof-of-concept

SOLID BIOSCIENCES

2023 Anticipated Milestones

Complete SGT-003 GLP tox for next-generation Duchenne therapy
1H 2023

Cardiac Capsid Library Complete Multiple Rounds of NHP Studies
2023

IND Submission for SGT-003
2H 2023

Initiation of Patient Dosing for SGT-003
Late-2023

Drug candidate selection and initiation of IND-enabling studies for AVB-202-TT

Continue to diversify pipeline through BD transactions

Approximately $214 million* in cash and investments as of December 31, 2022 expected to enable Solid to advance key strategic priorities into 2025

SOLID BIOSCIENCES

*Year-end financial results pending full audit

Thank You

SOLID BIOSCIENCES